| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919802 | Radiotherapy and Oncology | 2011 | 5 Pages |
Abstract
This study confirms the clinical feasibility of using HT to deliver TMI as selective dose boost modality after TBI. For patients with advanced leukemia targeted TMI after TBI may be a novel approach to increase radiation dose with low risk of severe toxicity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Renzo Corvò, Michele Zeverino, Stefano Vagge, Stefano Agostinelli, Salvina Barra, Gianni Taccini, Maria Teresa Van Lint, Francesco Frassoni, Andrea Bacigalupo,